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Introduction
Diabetes mellitus is associated with increased cardiac
morbidity and mortality (1). Cardiomyopathy occurs
commonly in diabetics independent of known risk fac-
tors such as coronary artery disease or hypertension (2).
Although little is known about the pathogenesis of dia-
betic cardiomyopathy, evidence is emerging that it may
be related to derangements in myocardial energy
metabolism (3, 4). Under normal conditions, myocar-
dial energy substrate preference varies in a dynamic
manner to fulfill the tremendous energy needs of the
postnatal mammalian heart. Whereas the fetal heart
relies primarily on glucose and lactate, the capacity for
mitochondrial fatty acid oxidation (FAO) increases
markedly after birth, providing the adult heart the
option of using glucose or fatty acids to meet energy
demands depending on dietary and physiologic condi-
tions (5). In diabetes, the capacity for cardiac energy
substrate switches becomes constrained due to the
importance of insulin in the control of myocardial glu-
cose uptake and utilization. In the uncontrolled dia-
betic state, the heart relies almost exclusively on FAO
for its ATP requirements (3, 4). This alteration in
myocardial energy substrate utilization could have
detrimental consequences such as increased myocar-
dial oxygen consumption due to excessively high mito-
chondrial oxidative flux. In addition, diabetic hearts
import fatty acids at a high rate (6–8), resulting in
myocardial lipid accumulation which predisposes the
myocytes to death and contractile dysfunction (9, 10).
Cardiac fatty acid utilization pathways are controlled,
in part, at the gene regulatory level. Recent studies have
demonstrated an important role for the nuclear recep-
tor peroxisome proliferator-activated receptor α
(PPARα) in the transcriptional control of genes
involved in cardiac fatty acid uptake and oxidation
(reviewed in ref. 11). PPARα, a ligand-activated tran-
scription factor, binds cognate DNA regulatory ele-
ments as a heterodimeric partner with the 9-cis retinoic
acid receptor RXR. Long-chain fatty acids and a variety
of related compounds serve as PPARα ligands. Genes
encoding FAO enzymes and proteins involved in cellu-
lar fatty acid import have been identified as PPARα tar-
gets (11). Basal expression of peroxisomal and mito-
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Recent evidence has defined an important role for PPARα in the transcriptional control of cardiac energy
metabolism. To investigate the role of PPARα in the genesis of the metabolic and functional derangements of
diabetic cardiomyopathy, mice with cardiac-restricted overexpression of PPARα (MHC-PPAR) were produced
and characterized. The expression of PPARα target genes involved in cardiac fatty acid uptake and oxidation
pathways was increased in MHC-PPAR mice. Surprisingly, the expression of genes involved in glucose trans-
port and utilization was reciprocally repressed in MHC-PPAR hearts. Consistent with the gene expression pro-
file, myocardial fatty acid oxidation rates were increased and glucose uptake and oxidation decreased in MHC-
PPAR mice, a metabolic phenotype strikingly similar to that of the diabetic heart. MHC-PPAR hearts exhibited
signatures of diabetic cardiomyopathy including ventricular hypertrophy, activation of gene markers of patho-
logic hypertrophic growth, and transgene expression–dependent alteration in systolic ventricular dysfunction.
These results demonstrate that (a) PPARα is a critical regulator of myocardial fatty acid uptake and utilization,
(b) activation of cardiac PPARα regulatory pathways results in a reciprocal repression of glucose uptake and
utilization pathways, and (c) derangements in myocardial energy metabolism typical of the diabetic heart can
become maladaptive, leading to cardiomyopathy.
J. Clin. Invest. 109:121–130 (2002). DOI:10.1172/JCI200214080.
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chondrial FAO enzymes is reduced in hearts of PPARα-
null mice (12–14). PPARα has also been shown to acti-
vate cardiac and hepatic FAO enzyme gene expression
during fasting when FAO rates increase (15, 16).
Recently, the PPARα gene regulatory pathway has
been implicated in the hepatic metabolic response to
diabetes mellitus. The expression of PPARα is elevated
in the livers of mice rendered diabetic by streptozotocin
(STZ) (17) or leptin receptor deficiency (db/db) (18).
Furthermore, the hepatic induction of PPARα target
genes in response to STZ-induced insulin deficiency
was found to be absent in PPARα-null mice (19). These
results suggest that one of the mechanisms whereby
cellular FAO rates are increased in the diabetic state
occurs via activation of the PPARα gene regulatory
pathway. In this study, mice with cardiac-specific over-
expression of PPARα were produced so that the meta-
bolic consequences of increased PPARα activity and its
effects on cardiac metabolism and function could be
evaluated in the absence of systemic alterations known
to occur in the diabetic state.
Methods
Animal studies and production of MHC-PPAR transgenic
mice. Diabetes was induced by a single intraperitoneal
injection of STZ (Sigma Chemical Co., St. Louis, Mis-
souri, USA; 180 mg/kg body weight). Diabetes was
confirmed by tail blood glucose monitoring (B-GLU-
COSE Analyzer; Hemacue AB, Angelholm, Sweden).
Mice with blood glucose of greater than 250 mg/dl
were considered diabetic. Male C57/BLKS/J-Leprdb
(db/db) and heterozygote (db/+) littermate mice were
obtained from The Jackson Laboratory (Bar Harbor,
Maine, USA). At 10 weeks of age, mice were sacrificed
for tissue collection.
A cDNA construct containing a 1.5-kb, NH2-terminal
FLAG epitope–tagged PPARα cDNA was cloned down-
stream of the cardiac α myosin heavy chain (MHC) pro-
moter (clone 26; gift of J. Robbins, The Children’s Hos-
pital Research Foundation, Cincinnati, Ohio, USA).
Transgenic mice were produced by microinjection of
the MHC-PPARα construct into fertilized one-cell
C57BL/6 × CBA/J F1 embryos. Functional and meta-
bolic endpoints were analyzed in pairs of MHC-PPAR
and littermate nontransgenic (NTG) mice ranging in
age from 8 to 16 weeks (22–30 g body weight).
Wy-14,643 (BIOMOL Research Laboratories Inc.,
Plymouth Meeting, Pennsylvania, USA) was incorpo-
rated into standard rodent chow (0.1% weight/weight;
Bio-Serv Inc., Frenchtown, New Jersey, USA). Mice were
given ad libitum access to matched control chow (no.
F3028, Bio-Serv Inc.) or Wy-14,643–containing chow
and killed for sample collection 1 week later.
For the fasting studies, male and female littermate
mice were separated into individual cages at the begin-
ning of each experiment. Mice were fasted for 24 hours.
Control mice were allowed ad libitum access to stan-
dard laboratory chow (Diet 5053; Purina Mills Inc., St.
Louis, Missouri, USA).
All animal experiments were approved by the Ani-
mal Studies Committee of Washington University
School of Medicine.
Micro–positron emission tomography studies. For
micro–positron emission tomography (microPET)
analyses of cardiac 11C-palmitate and 18F-fluo-
rodeoxyglucose (18F-FDG) uptake, mice were fasted for
6 hours and then anesthetized using isoflurane. A ster-
ile microcatheter was placed within the external jugu-
lar vein. The first imaging sequence was initiated, and
after a 3-second delay, a bolus injection of 0.3 mCi of
11C-palmitate was administered via the jugular
catheter. MHC-PPAR and NTG littermate mice were
imaged side by side with the microPET-R4 camera
(Concorde Microsystems Inc., Knoxville, Tennessee,
USA) for 40 minutes. After data acquisition, there was
a 30-minute “wash-out” followed by a second scan after
a bolus injection of 0.5 mCi of 18F-FDG.
Mouse isolated working heart preparation. Mouse work-
ing heart perfusions were carried out as described by
Belke et al. (20). Working hearts were perfused with
Krebs-Henseleit solution containing 5 mM glucose,
100 µU/ml insulin, and 0.4 mM palmitate. Myocardial
fatty acid and glucose oxidation rates were determined
by the quantitative collection of 3H2O or 14CO2 pro-
duced by hearts perfused with buffer containing 
[9,10-3H]palmitate or [U-14C]glucose (20).
Echocardiographic studies. Transthoracic M-mode and
two-dimensional echocardiography was performed on
conscious mice using an Acuson Sequoia 256 Echocar-
diography system (Acuson Corp., Mountain View, Cal-
ifornia, USA) as described (10).
Histologic analyses. After harvest, a midventricular slice
of myocardium was snap-frozen in a cryomold for sec-
tioning. To detect neutral lipid, the sections were stained
with oil red O and counterstained with hematoxylin.
RNA and protein blot analyses. The protocols for total
RNA isolation and Northern blotting have been
described (13). Cardiac ventricle was used as the source
for RNA isolation unless noted otherwise. Northern
blot analyses were performed using the radiolabeled
cDNA probes described in the text. Band intensities
were quantified by phosphorimaging analysis and nor-
malized to the expression of GAPDH.
For Western blotting studies to detect PPARα, cardiac
protein extracts were prepared as described (21) using
an antibody directed against murine PPARα (gift of
J.W. Woods and J.P. Berger, Merck Research Laborato-
ries, Rahway, New Jersey, USA). Total cell membrane
protein extracts were prepared as described (10) for use
in immunoblot studies with anti–acyl-CoA oxidase
(anti-ACO), anti-GLUT1, anti-GLUT4, and anti-actin
(Sigma Chemical Co.).
Determination of carnitine palmitoyltransferase I enzymat-
ic activity. Carnitine palmitoyltransferase I (CPT I) activ-
ity was determined in isolated cardiac mitochondria
from MHC-PPAR and NTG mice by measuring the for-
mation of palmitoyl-[14C]-carnitine from palmitoyl-
CoA and [14C]-carnitine as described (22).
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Analysis of myocardial triacylglycerol levels. The quanti-
tative analysis of myocardial triacylglycerol (TAG)
species has been described (23). In brief, lipids were
extracted from mouse heart using a modified Bligh and
Dyer technique in the presence of internal standards
for electrospray ionization mass spectroscopic (ESIMS)
analysis. ESIMS analyses of TAG were performed using
a Finnigan TSQ-7000 spectrometer (Finnigan Corp.,
San Jose, California, USA) equipped with an electro-
spray ion source as described previously (23).
Serum chemistries. Serum nonesterified fatty acid
(NEFA), TAG, glucose, and insulin levels were deter-
mined by enzymatic, colorimetric assays by the Core
Laboratory of the General Clinical Research Center at
Washington University School of Medicine.
Statistical analysis. Statistical comparisons were made
using ANOVA coupled to Scheffe’s test. All data are
presented as means ± SEM, with a statistically signifi-
cant difference defined as a P value less than 0.05.
Results
The PPARα gene regulatory pathway is activated in the dia-
betic mouse heart. We sought to determine whether the
increased rates of myocardial FAO known to occur in
the diabetic heart are associated with activation of the
PPARα gene regulatory pathway. Northern blot analy-
ses were performed using total RNA isolated from ven-
tricular tissue of mice rendered diabetic for 6 weeks by
administration of STZ. The expression of the genes
encoding PPARα and its cardiac-enriched coactivator
PPARγ coactivator 1 (PGC-1) was increased in hearts of
STZ-treated mice compared with vehicle-injected lit-
termates (Figure 1a). In addition, the expression of
PPARα target genes encoding mitochondrial (muscle-
type CPT; M-CPT I) and peroxisomal (ACO) FAO
enzymes was upregulated two- to threefold in the
hearts of mice treated with STZ.
The expression of PPARα target genes was also acti-
vated in hearts of diabetic db/db mice, which are obese
and severely insulin-resistant due to a leptin receptor
defect. The expression of PPARα-responsive genes
(ACO and M-CPT I) was elevated in the hearts of db/db
mice compared with db/+ littermate controls (Figure
1b). In contrast to the insulin-deficient mice, PPARα
gene expression was not altered in db/db mouse heart,
but levels of PGC-1 mRNA were significantly increased
compared with those in controls (Figure 1b). Taken
together, these data indicate that the cardiac PPARα
regulatory pathway and downstream genes involved in
cellular FAO are activated in insulin-deficient and
insulin-resistant forms of diabetes mellitus.
Production of transgenic mice with cardiac-restricted over-
expression of PPARα. We hypothesized that chronic acti-
vation of the cardiac PPARα regulatory pathway
would lead to cardiac energy metabolic derangements
and functional abnormalities similar to the diabetic
heart. To establish a mouse model with constitutively
increased activity of cardiac PPARα, transgenic mice
were generated in which FLAG epitope–tagged PPARα
was overexpressed in postnatal cardiac ventricle via the
cardiac α myosin heavy chain gene promoter (MHC-
PPAR mice). Four independent lines of MHC-PPAR
transgenic mice were established (404-3, 402-2, 404-11,
and 404-4) exhibiting a wide range of cardiac-restrict-
ed transgene expression (Figure 2a). PPARα protein
levels were approximately 135-fold (404-3), 80-fold
(402-2), 40-fold (404-11), and 15-fold (404-4) more
abundant in the cardiac ventricles of transgenic ani-
mals compared with NTG littermates. Transgenic
mice from each of the lines bred normally and litter
sizes were similar to those of NTG mice. The 6-month
mortality of the transgenic mice was not different
from that of NTG littermates.
Increased expression of PPARα target genes involved in car-
diac FAO in MHC-PPAR mice. The expression of PPARα
target genes involved in FAO was characterized in the
hearts of MHC-PPAR mice. Levels of mRNA encoding
ACO were significantly higher (approximately
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Figure 1
Increased expression of PPARα target genes in diabetic mouse
myocardium. (a) Bars represent mean (± SEM) mRNA levels as
determined by phosphorimager analysis of Northern blots per-
formed with RNA isolated from mouse ventricle, shown as arbitrary
units (AU) corrected for GAPDH signal intensity and normalized to
the value of vehicle-injected controls (= 1.0). *P < 0.05 versus vehi-
cle-injected mice (n = 4 for each group). A representative autoradi-
ograph of the Northern blot studies is shown at the right. Each lane
contained 15 µg total RNA isolated from mice 6 weeks after an
injection of saline (vehicle) or a single dose of STZ (180 mg/kg). The
blot was sequentially hybridized with the radiolabeled cDNA probes
shown on the left. (b) Increased expression of PPARα target genes
in db/db diabetic mice. Bars represent mRNA levels shown as arbi-
trary units (AU) corrected for GAPDH signal intensity and normal-
ized to the value of db/+ littermate controls (= 1.0). *P < 0.05 ver-
sus db/+ littermate controls; n = 5 for each group. A representative
autoradiograph is shown at the right. Each lane contained 15 µg of
ventricular total RNA isolated from 10-week-old heterozygote con-
trol (db/+) or littermate diabetic (db/db) mice.
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twofold) in myocardium of the highest (404-3) and
lowest (404-4) transgene-expressing lines of MHC-
PPAR mice than in NTG littermate controls (Figure 2b
and Table 1). M-CPT I mRNA levels were also higher
in the hearts of MHC-PPAR (404-3) mice than in the
hearts of NTG controls (Figure 2b and Table 1). To
investigate the possibility that PPARα ligand was lim-
iting for full activation of its target genes in MHC-
PPAR mice, ACO and M-CPT I gene expression was
characterized in MHC-PPAR and NTG littermate mice
fed the synthetic PPARα activator Wy-14,643. In NTG
mice, administration of Wy-14,643 (0.1% by weight in
chow) for 7 days resulted in the marked induction of
ACO mRNA expression in liver (data not shown), but
not in heart (Figure 2b). In contrast, Wy-14,643 caused
a robust (over ninefold) induction of ACO gene expres-
sion in hearts of MHC-PPAR (404-3) mice (Figure 2b
and Table 1). ACO protein levels were also increased in
MHC-PPAR (404-3) hearts (Figure 2b). Interestingly,
the induction of ACO protein levels was more robust
than that observed for the corresponding mRNA lev-
els in MHC-PPAR mice (Figure 2b and data not
shown). Wy-14,643–mediated induction of cardiac
ACO gene expression was greater in the highest trans-
gene expressing line (404-3) than in the lowest express-
ing line (404-4), suggesting that ligand is limiting for
full activation of this PPARα target gene in MHC-
PPAR mice. However, M-CPT I mRNA levels were
induced to a similar extent (about twofold) by PPARα
activator in both 404-3 and 404-4 lines, suggesting that
additional factors are limiting for the PPARα-mediat-
ed transcriptional activation of this gene. CPT I enzy-
matic activity was also increased in MHC-PPAR heart
compared with controls (Figure 2b). The levels of mal-
onyl-CoA, an endogenous inhibitor of CPT I, were not
significantly different in the hearts of NTG and 
MHC-PPAR mice (data not shown). Given that ACO
and M-CPT I catalyze rate-limiting steps in peroxiso-
mal and mitochondrial β-oxidation, respectively, these
results indicate that the capacity for cellular FAO is
increased in the hearts of MHC-PPAR mice.
Recent studies have shown that the mitochondrial
uncoupling protein UCP3 is a PPARα target (24) and that
its expression is increased in the hearts of STZ-induced
diabetic rats (25). Accordingly, the cardiac expression of
the UCP2 and UCP3 genes was evaluated in the MHC-
PPAR mice. The levels of UCP2 mRNA (nearly twofold)
and, to a greater extent, UCP3 mRNA (approximately
fivefold) were significantly greater in MHC-PPAR heart
than in that of NTG controls (Table 1).
Activation of the cardiac fatty acid uptake pathway in MHC-
PPAR mice. The expression of PPARα target genes
encoding proteins involved in cellular fatty acid import
(fatty acid transport protein 1 [FATP1] and CD36) and
thioesterification (fatty acyl-CoA synthetase 1; FACS1)
was also evaluated in MHC-PPAR mice. At baseline,
FATP1, CD36, and FACS1 mRNA levels were not sig-
nificantly different in MHC-PPAR heart (404-3 and 404-
4) compared with controls. However, Wy-14,643
administration significantly induced the cardiac
expression of each in MHC-PPAR mice, but not in NTG
controls (Table 1). The inducible overexpression of
FATP1, CD36, and FACS1 in MHC-PPAR mice sug-
gested that, under physiologic circumstances in which
PPARα ligand levels rise, myocardial fatty acid uptake
would increase, possibly beyond the capacity for oxida-
tion. Indeed, a histologic signature of the diabetic heart
is myocyte lipid accumulation due to increased
myocyte fatty acid import. Fasting is known to increase
circulating NEFA levels, leading to activation of PPARα
in heart and liver (15, 16). Therefore, the histologic
appearance of myocardium from MHC-PPAR and
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Figure 2
Increased expression of PPARα target genes in hearts of transgenic
mouse lines (MHC-PPAR mice) that express PPARα in a cardiac-
restricted manner. (a) Representative autoradiographs of Northern
(top) and Western (middle) blot studies performed with heart sam-
ples from 6-week-old mice from four independent MHC-PPAR lines.
At the exposure shown, endogenous PPARα could not be detected
in NTG samples. FLAG-PPARα protein was detected in the transgenic
mice using an antibody directed against either PPARα (shown here)
or FLAG (data not shown). Cardiac-specific expression of FLAG-
PPARα mRNA was confirmed by Northern blot analysis performed
with multiple tissues (bottom panel represents the 402-2 line). H,
heart; BAT, brown adipose tissue; SM, skeletal muscle; K, kidney; L,
liver. (b) The expression of PPARα target genes is increased and
inducible by PPARα activator in the hearts of MHC-PPAR mice. The
graphs represent the results of Northern blot analyses performed
with the probes indicated using RNA isolated from ventricle of male
and female NTG or MHC-PPAR littermate mice fed control chow or
a 7-day course of chow containing Wy-14,643 (0.1% wt/wt). Bars
represent mean mRNA levels (arbitrary units, AU) quantified as
described in Methods (n ≥ 7 mice for each group). The inset shows
representative autoradiographs of Western blot analyses. *P < 0.05
versus NTG littermate mice. **P < 0.05 versus MHC-PPAR mice fed
control chow and NTG mice. Far right: Bars represent mean malonyl-
CoA−inhibited CPT enzyme activity (n = 3 for each group). †P < 0.05
versus NTG littermate mice.
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NTG mice was evaluated following a short-term fast. In
the fasted state, oil red O staining revealed substantial
neutral lipid droplet accumulation in cardiac myocytes
from MHC-PPAR mice, whereas NTG littermates
remained mainly oil red O–negative (Figure 3a). Car-
diac sections from the nonfasted MHC-PPAR and NTG
groups were negative for neutral lipid (data not shown).
To quantify and characterize the lipid accumulation
in MHC-PPAR hearts, myocardial lipid was extracted
from fed and fasted transgenic and NTG littermate
mice for ESIMS analysis. The myocardial lipid content
in MHC-PPAR mice was not significantly different
from that of NTG controls under nonfasted conditions
(Figure 3b). However, as predicted by the oil red O
staining pattern, myocardial TAG levels were marked-
ly higher in fasted MHC-PPAR mice than in controls.
Levels of long-chain fatty acid–containing TAG (16:0,
18:1, 18:2) were dramatically increased in fasted MHC-
PPAR mice compared with NTG mice (Figure 3b).
Although the quantity of myocardial TAG was much
greater in MHC-PPAR mice, the profile of TAG species
was not different between NTG and MHC-PPAR mice
(Figure 3b). Serum NEFA levels were similar in NTG
and MHC-PPAR mice in both the fasted and the fed
states (fed, 0.80 ± 0.04 vs. 0.86 ± 0.02 µM, respectively;
fasted, 1.34 ± 0.18 vs. 1.44 ± 0.15 µM, respectively), indi-
cating that the supply of circulating NEFA was equiva-
lent in both genotypes.
The observed increase in neutral lipid content in the
fasted MHC-PPAR myocardium suggested that path-
ways involved in TAG synthesis were induced. The
myocardial expression of genes encoding glycerol-3-
phosphate acyltransferase (GPAT) and diacylglycerol
acyltransferase (DGAT), two key enzymes involved in
the esterification of fatty acids to TAG, was signifi-
cantly increased by PPARα overexpression at base line
and further with fasting (Figure 3c). The cardiac expres-
sion of adipophilin, a putative fatty acid–binding pro-
tein that associates with lipid droplets, was also
increased in MHC-PPAR mice (Figure 3c). Surprising-
ly, the cardiac expression of the genes encoding the
fatty acid import proteins FATP1, FACS1, and CD36
was not significantly greater in the fasted MHC-PPAR
mice than in NTG mice (data not shown).
Reduced expression of cellular glucose import proteins and
utilization enzymes in the hearts of MHC-PPAR mice. A
metabolic signature of the diabetic heart is reduced
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Figure 3
Myocardial lipid accumulation in fasted MHC-PPAR mice. (a) Pho-
tomicrographs depicting the histologic appearance of ventricular tis-
sue from NTG and MHC-PPAR mice following a 24-hour fast at low
(upper panels) and high (lower panels) magnification. Frozen tissue
sections were stained with oil red O. Red droplets indicate neutral
lipid staining. (b) Lipid profile of mouse ventricle samples prepared
from MHC-PPAR or NTG mice given ad libitum access to food or
fasted for 24 hours. Lipid species were separated and analyzed using
ESIMS (see Methods). Mass/charge (m/z) ratios of 814, 840, and
864 denote TAGs containing fatty acyl groups containing chain
lengths of 16:0/16:0/16:0, 16:0/16:0/18:1, and 16:0/18:1/18:2, as
shown at the top. (c) Representative autoradiographs of Northern
blot analyses performed with total RNA isolated from cardiac ven-
tricle of mice fed ad libitum or after a 24-hour fast using cDNA
probes for diacylglyceride acyltransferase (DGAT), glycerol-3-phos-
phate acyltransferase (GPAT), and adipophilin. Ethidium bromide−
stained 28S rRNA is shown as a control for loading.
Table 1
PPARα target gene expression in MHC-PPAR mice
404-3 Control chow Wy-14,643 chow (0.1%)
Gene NTG MHC-PPAR NTG MHC-PPAR
M-CPT I 1.0 ± 0.25 1.5 ± 0.11A 1.4 ± 0.13 2.3 ± 0.20A
ACO 1.0 ± 0.20 2.4 ± 0.13A 1.4 ± 0.32 9.4 ± 0.07A
FATP1 1.0 ± 0.30 1.0 ± 0.09 1.6 ± 0.42 1.9 ± 0.24A
FACS1 1.0 ± 0.20 1.3 ± 0.18 1.5 ± 0.15 3.2 ± 0.40A
CD36 1.0 ± 0.32 1.1 ± 0.22 0.89 ± 0.45 2.4 ± 0.30A
UCP2 1.0 ± 0.25 1.9 ± 0.26A 2.0 ± 0.40 2.6 ± 0.45
UCP3 1.0 ± 0.33 5.0 ± 0.10A 4.6 ± 0.11 6.1 ± 0.06A
404-4
M-CPT I 1.0 ± 0.10 1.3 ± 0.15 0.9 ± 0.28 2.0 ± 0.30A
ACO 1.0 ± 0.25 2.0 ± 0.40 1.6 ± 0.21 4.2 ± 0.82A
FACS1 1.0 ± 0.30 1.3 ± 0.30 2.1 ± 0.11 3.1 ± 0.31A
CD36 1.0 ± 0.21 1.5 ± 0.24 0.9 ± 0.23 2.7 ± 0.13A
Values represent mean (± SEM) arbitrary units normalized to that of the NTG
mice (= 1.0) without Wy-14,643 treatment based on phosphorimager analysis
of Northern blot studies (n ≥ 7 for each group). ASignificant difference (P < 0.05)
compared with NTG littermate within the corresponding treatment group.
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glucose uptake and utilization (3, 4, 26). The myocar-
dial expression of genes encoding glucose transporters
(GLUT1 and GLUT4) and the glycolytic enzyme phos-
phofructokinase (PFK) was evaluated in MHC-PPAR
mice. Levels of GLUT4 mRNA were markedly lower
(over 50%) in hearts of 404-3 MHC-PPAR mice than in
those of controls (Figure 4). Treatment with Wy-14,643
resulted in a further downregulation of GLUT4 gene
expression in MHC-PPAR mice and in NTG mice (Fig-
ure 4). Immunoblot analysis also revealed a striking
reduction (70–75%) in GLUT4 protein levels in total
cell membrane–enriched protein extracts prepared
from hearts of MHC-PPAR mice compared with con-
trols (Figure 4). In contrast, GLUT1 mRNA and protein
levels were not affected by PPARα overexpression at
base line or following Wy-14,643 treatment (Figure 4).
PFK gene expression was also reduced in MHC-PPAR
hearts at base line and by Wy-14,643 treatment (Figure
4). These data indicate that the expression of genes
involved in insulin-responsive glucose transport and
glycolysis is downregulated in the MHC-PPAR heart.
The expression of pyruvate dehydrogenase kinase 4
(PDK4), a negative regulator of glucose oxidation via
its inhibitory effects on the pyruvate dehydrogenase
complex, was recently shown to be increased in diabet-
ic heart (27). Compared with untreated NTG controls,
cardiac PDK4 mRNA levels were fourfold higher in
MHC-PPAR mice fed control chow and 14-fold higher
after PPARα activator treatment (Figure 4). Wy-14,643
treatment also led to a fourfold activation of PDK4
expression in NTG mice. Cardiac PDK4 protein levels
were also higher in MHC-PPAR mice (data not shown).
Taken together, these data indicate that multiple steps
in the cellular glucose utilization pathway are inhibit-
ed at the gene regulatory level in the MHC-PPAR heart.
Altered myocardial fatty acid and glucose uptake and uti-
lization rates in MHC-PPAR mice. The results of the gene
expression studies predicted that fatty acid uptake is
increased and glucose uptake reciprocally decreased in
the hearts of MHC-PPAR mice compared with NTG
controls. To investigate myocardial fatty acid and glu-
cose import rates in vivo in MHC-PPAR mice,
microPET studies were performed. The myocardial
uptake of 11C-palmitate was increased in MHC-PPAR
(404-3 line) mice compared with NTG littermate con-
trols (representative image, Figure 5a). Conversely, 
18F-FDG uptake was substantially lower in hearts of
MHC-PPAR mice than in those of NTG littermates.
Time-activity curves demonstrated that accumulation
of 11C-palmitate into the MHC-PPAR heart was signif-
icantly increased and 18F-FDG accretion decreased for
20 minutes following bolus injection of the labeled
substrates (Figure 5a). Serum NEFA (0.80 ± 0.04 vs.
0.86 ± 0.02 µM), glucose (197 ± 14.6 vs. 189 ± 12.5
mg/dl), and insulin (0.82 ± 0.25 vs. 0.67 ± 0.21 ng/ml)
levels were similar in MHC-PPAR and NTG littermate
mice, respectively.
To assess myocardial substrate utilization in MHC-
PPAR mice, the oxidation of [9,10-3H]palmitate and 
[U-14C]glucose was measured in working hearts isolated
from MHC-PPAR or NTG littermate mice. We found
that the mean rate of [3H]palmitate oxidation was 64%
higher in hearts isolated from MHC-PPAR (402-2 line)
mice than in NTG hearts (294 ± 44 vs. 179 ± 9
nmol/min/g dry weight; P < 0.05; Figure 5b). Strikingly,
mean glucose oxidation rates were diminished by 63% in
MHC-PPAR hearts compared with controls (302 ± 150
vs. 824 ± 72 nmol/min/g dry weight; P < 0.05; Figure 5b).
These data, which are consistent with the results of the
gene expression and PET studies, indicate that hearts of
MHC-PPAR mice depend on fatty acid for the genera-
tion of energy to a significantly greater extent than do
hearts of NTG mice, a substrate utilization profile simi-
lar to that of the diabetic heart.
Cardiac hypertrophy and ventricular dysfunction in MHC-
PPAR mice. The initial stages of diabetic cardiomyopa-
thy are characterized by ventricular hypertrophy and
diastolic dysfunction (28). In severe cases, cardiac
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Figure 4
Altered expression of genes involved in glucose utilization pathways
in MHC-PPAR heart. The graphs represent the results of Northern
blot analyses performed with total RNA isolated from the cardiac
ventricles of MHC-PPAR or littermate NTG mouse hearts. The blots
were sequentially hybridized with radiolabeled cDNA probes for
GLUT4, GLUT1, PFK, and pyruvate dehydrogenase kinase 4 (PDK4).
Bars represent mean mRNA levels as determined by phosphorimager
analysis (n ≥ 7 for each group) corrected to the GAPDH signal and
normalized to that of the NTG mice treated with control chow (= 100
or 1.0). Groups receiving a 7-day course of Wy-14,643 are denoted
at the bottom of each graph. Top: Representative autoradiographs
of Western blot analyses using anti-GLUT4 or anti-GLUT1 antibod-
ies with protein extracts containing total cell membrane−enriched
fractions of cardiac ventricle from MHC-PPAR mice and NTG litter-
mates. *P < 0.05 versus NTG littermate mice fed control chow. 
**P < 0.05 versus MHC-PPAR mice fed control chow and NTG mice.
Bars represent the mean of at least seven individual animals.
Downloaded on June  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/14080
abnormalities can progress to systolic ventricular dys-
function and overt congestive heart failure. As an ini-
tial step to determine whether the metabolic derange-
ments resulting from PPARα overexpression lead to
cardiac dysfunction similar to that of diabetic car-
diomyopathy, hearts from age- and sex-matched mice
from all four MHC-PPAR lines were examined for signs
of ventricular hypertrophy compared with NTG litter-
mates. MHC-PPAR mice from each of the four lines
exhibited an increased biventricular weight/body
weight ratio in a pattern that was generally dependent
upon the level of transgene expression (Figure 6a). His-
tologic examination of left ventricular (LV) tissue sec-
tions stained with hematoxylin and eosin or trichrome
revealed no obvious abnormalities in myocardial
cytoarchitecture, except for myocyte hypertrophy 
(3-month-old MHC-PPAR mice; data not shown). The
expression of hypertrophic growth marker genes brain-
type natriuretic peptide (BNP), atrial natriuretic factor
(ANF), and skeletal α-actin was induced in ventricle of
6-week-old 404-3 MHC-PPAR mice (Figure 6b) and in
less highly expressing lines (data not shown). In con-
trast, the ratio of cardiac α myosin heavy chain to 
β myosin heavy chain mRNA levels was not signifi-
cantly different between the two groups (data not
shown). As has been reported in the diabetic heart (25,
29), the expression of the genes encoding sarco-
plasmic/endoplasmic reticulum Ca2+ ATPase 2a
(SERCA2a) and its regulatory protein phospholamban
(PLB) was reduced in MHC-PPAR hearts (Figure 6b).
Echocardiography was performed on animals from
all four MHC-PPAR lines. As shown in Figure 6c and
Table 2, posterior wall thickness was increased in the
404-3 and 402-2 lines of MHC-PPAR mice. LV chamber
dilatation, as determined by measurement of systolic
(LVIDs) and diastolic (LVIDd) internal diameters, was
increased in the most highly expressing line of MHC-
PPAR mice (404-3)compared with littermate controls.
Fractional shortening was significantly reduced in the
three most highly expressing lines compared with
NTG littermates (Table 2; Figure 6c). These data indi-
cate that MHC-PPAR mice develop cardiac hypertro-
phy and ventricular dysfunction in a transgene expres-
sion level-dependent manner.
Discussion
The energy metabolic alterations associated with dia-
betic cardiomyopathy include excessive rates of myocar-
dial fatty acid uptake and oxidation coupled with
reduced glucose utilization. In an attempt to model the
metabolic derangements of the diabetic heart, we have
generated mice with cardiac-specific overexpression of
the nuclear receptor PPARα. This strategy was
employed so that the impact of altered myocardial ener-
gy metabolism on cardiac function could be assessed in
the absence of the systemic diabetic state. We found that
the MHC-PPAR mice exhibit a cardiac metabolic phe-
notype that is strikingly similar to that of the diabetic
heart. Several lines of evidence support this conclusion.
First, as in the diabetic heart, the expression of genes
involved in the myocardial fatty acid utilization path-
way is activated in MHC-PPAR hearts. Second, a recip-
rocal downregulation of the myocardial glucose trans-
port, glycolytic, and glucose oxidation pathways occurs
in the transgenic mice. Third, fatty acid uptake and oxi-
dation rates are increased whereas glucose uptake and
oxidation is abnormally suppressed in the hearts of
MHC-PPAR mice. Lastly, the transgenic mice exhibit
evidence of altered cardiac myocyte lipid balance as has
been described for the diabetic heart.
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Figure 5
Myocardial palmitate utilization is increased and FDG reduced in
MHC-PPAR mice. (a) The top two panels contain representative
images of 11C-palmitate and 18F-FDG uptake into myocardium as
assessed by microPET in NTG and MHC-PPAR mice following a 
6-hour fast. The relative amount of tracer uptake into the mouse
heart 15 seconds after bolus injection of 11C-palmitate or 18F-FDG
into the jugular vein is indicated by the color scale (0−100). The
arrows indicate the cardiac field. As shown in the upper panel, the
color field is increased into the red scale in the hearts of MHC-PPAR
mice infused with 11C-palmitate, which is indicative of enhanced
myocardial uptake of fatty acid. Conversely, uptake of 18F-FDG is
substantially lower in hearts of MHC-PPAR mice than in those of
NTG littermates. The graphs below the images contain time-activi-
ty curves for the cardiac fields. (b) Myocardial palmitate oxidation
is increased and glucose oxidation reduced in MHC-PPAR mice. The
oxidation of [9,10-3H]palmitate and [U-14C]glucose was assessed
in isolated working hearts (as described in Methods) of MHC-PPAR
(line 402-2; n = 6) or NTG littermate (n = 4) mice fed control chow.
Bars represent mean (± SEM) oxidation rates expressed as
nanomoles of substrate oxidized per minute per gram dry mass. 
*P < 0.05 versus NTG littermate mice.
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The cardiac function of MHC-PPAR mice was evalu-
ated to determine whether, as speculated, energy meta-
bolic derangements lead to cardiomyopathy. We found
that the MHC-PPAR hearts exhibit ventricular hyper-
trophy in association with activated expression of
hypertrophic gene markers. Moreover, as occurs in
severe forms of diabetic cardiomyopathy, the MHC-
PPAR mouse lines with the highest level of transgene
expression developed LV chamber dilatation and sys-
tolic ventricular dysfunction. Taken together, these
results strongly suggest that the energy metabolic
shifts of the diabetic heart become maladaptive and
contribute to the development of cardiac dysfunction.
An important question raised by our results relates to
the mechanistic link between altered myocardial ener-
gy metabolism and cardiac dysfunction in the diabetic
heart. It is possible that in the context of high-level
fatty acid uptake and mitochondrial β-oxidation, toxic
lipid intermediates accumulate within cardiac
myocytes. For example, a mismatch between the rates
of fatty acid import and oxidation may result in cardiac
myocyte lipid accumulation such as that observed in
MHC-PPAR mice, which could cause contractile dys-
function or cell death. Indeed, previous studies have
shown that lipid often accumulates in the myocardium
of diabetic animals (7–9). A recent study by Chiu et al.
(10) has shown that myocardial lipid accretion due to
increased fatty acid uptake leads to myocyte apoptosis
and cardiomyopathy — a “lipotoxic” effect. However, we
did not find evidence for increased myocardial apopto-
sis in the MHC-PPAR mice (data not shown). Altered
mitochondrial function could also play a role in the
cardiac dysfunction observed in the MHC-PPAR mice.
For example, increased mitochondrial flux may lead to
the generation of harmful reactive oxygen species. The
observed increase in UCP3 gene expression in the
MHC-PPAR and diabetic heart (25) may also relate to
the development of cardiac dysfunction. However, the
role of UCP3 as a bona fide mitochondrial respiratory
uncoupler in heart remains unclear. Increased respira-
tory uncoupling could actually be adaptive in the set-
ting of increased mitochondrial flux, such as occurs in
the diabetic and MHC-PPAR heart. Lastly, reliance on
FAO for ATP production, which results in higher mito-
chondrial oxygen consumption costs compared with
glycolysis and glucose oxidation, could also contribute
to ventricular dysfunction.
Reduced myocardial glucose utilization may also
account for the observed cardiac dysfunction in the
MHC-PPAR mice. Previous studies of the ischemic
and reperfused heart indicate that a reduction in gly-
colysis and glucose oxidation is associated with
diminished ventricular function (30–32). In addition,
the hearts of GLUT4-deficient mice develop profound
dysfunction during ischemia (33). The mechanisms
for these observations are unknown but could involve
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Figure 6
Induction of the cardiac hypertrophic growth gene regulatory
program and left ventricular dysfunction in MHC-PPAR mice. (a)
Bars represent mean biventricular-to-body-weight (BV/BW)
ratios (n ≥ 20 for each group) for male and female MHC-PPAR
and NTG littermate mice. All mice were between 2 and 4 months
of age. *P < 0.05 versus NTG littermate mice. (b) Representative
autoradiographs of Northern blot analyses performed with total
RNA isolated from cardiac ventricle from 6-week-old NTG or
MHC-PPAR (404-3 line) mice using cDNA probes for skeletal
(Sk.) α-actin, brain-type natriuretic peptide (BNP), atrial natri-
uretic factor (ANF), phospholamban (PLB), and sarcoplas-
mic/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a). (c) Ven-
tricular dysfunction in MHC-PPAR mice is related to transgene
expression level. Representative two-dimensional guided M-
mode echocardiographic images of the left ventricle obtained
from the parasternal view at the midventricular level of NTG and
four different transgenic lines of female mice at 2 months of age.
Table 2
LV function in MHC-PPAR mice
404-3 line 402-2 line 404-11 line 404-4 line
NTG MHC-PPAR NTG MHC-PPAR NTG MHC-PPAR NTG MHC-PPAR
HR 678 ± 12 628 ± 5 631 ± 18 649 ± 11 673 ± 27 695 ± 22 646 ± 18 599 ± 50
LVPWd 0.72 ± 0.01 0.81 ± 0.07A 0.70 ± 0.02 0.80 ± 0.01A 0.72 ± 0.03 0.74 ± 0.02 0.66 ± 0.03 0.87 ± 0.23
LVIDd 3.3 ± 0.04 3.6 ± 0.04A 3.2 ± 0.07 3.2 ± 0.05 3.3 ± 0.10 3.5 ± 0.5 3.6 ± 0.3 3.5 ± 0.1
LVIDs 1.4 ± 0.03 2.1 ± 0.05A 1.4 ± 0.04 1.5 ± 0.05 1.4 ± 0.07 1.8 ± 0.16 1.2 ± 0.37 1.6 ± 0.10
RWT 0.44 ± 0.01 0.45 ± 0.01 0.46 ± 0.02 0.51 ± 0.01 0.45 ± 0.03 0.43 ± 0.02 0.37 ± 0.02 0.50 ± 0.01
FS 58.5 ± 0.7 43.2 ± 1A 57.2 ± 1 52.2 ± 1A 57.4 ± 1.4 49.6 ± 3A 58 ± 1 56 ± 3
Values represent mean (± SEM) (n ≥ 7 for each group). AP < 0.05 compared with NTG littermate control mice. HR, heart rate; LVPWd, left ventricle posterior
wall thickness at diastole; LVIDd, LV internal diameter at diastole; LVIDs, LV internal diameter at systole; RWT, relative wall thickness; FS, fractional shortening.
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distinct intracellular channeling routes of ATP pro-
duced by glucose oxidation or effects related to oxy-
gen consumption efficiency.
The MHC-PPAR hearts exhibit several interesting
lipid metabolic alterations in addition to the expected
increase in FAO rates. First, the microPET studies
demonstrated increased myocardial palmitate uptake.
Secondly, TAGs accumulate in MHC-PPAR cardiac
myocytes following a short-term fast, which serves to
acutely increase circulating NEFA levels. This latter
observation is interesting because TAG accumulates in
the diabetic heart (7, 8). The results of the PET and fast-
ing studies suggest that increased myocardial fatty acid
uptake leads to a positive myocyte lipid balance in the
MHC-PPAR heart. However, the mechanism involved
in the increased myocardial fatty acid uptake remains
unknown, because the fasting-induced increase in the
expression of proteins involved in fatty acid import was
not significantly greater in MHC-PPAR hearts. In addi-
tion, we cannot exclude the possibility that lipid syn-
thesis pathways, including GPAT and DGAT, are acti-
vated directly by PPARα in the MHC-PPAR heart.
However, we have not found evidence that GPAT or
DGAT is a PPARα target gene based on expression lev-
els in fasted PPARα–/– mice (B.N. Finck and D.P. Kelly,
unpublished data).
A surprising observation in this study relates to the
dramatically altered expression of genes involved in glu-
cose transport, glycolysis, and glucose oxidation in the
hearts of MHC-PPAR mice. The inhibitory effects of
FAO on glucose utilization in heart were first described
as the “glucose fatty-acid cycle” by Randle et al. (34).
This effect involves inhibition of the pyruvate dehydro-
genase complex by elevated acetyl-CoA/CoA and
NADH/NAD+ ratios generated by increased β-oxidative
flux. However, the reduction in myocardial glucose uti-
lization observed in MHC-PPAR mice likely involves
mechanisms distinct from that proposed for the Ran-
dle cycle, because it includes a gene regulatory compo-
nent and involves effects on glucose transport. Fatty
acid–induced insulin resistance has been well described
and has been proposed to play a role in the development
of type 2 diabetes (35, 36). Recent evidence indicates
that fatty acid–induced insulin resistance involves alter-
ations at the level of glucose transport secondary to
derangements in insulin signaling (37, 38). Our results
suggest that glucose transport can be inhibited in heart
as a result of primary alterations in cellular lipid metab-
olism driven by PPARα. Consistent with the notion that
increased cellular lipid uptake can serve as the initial
trigger for alterations in insulin sensitivity, Kim et al.
(39) recently demonstrated that transgenic overexpres-
sion of lipoprotein lipase in skeletal muscle caused
insulin resistance in nondiabetic mice.
The derangements in cardiac glucose utilization we
observed in MHC-PPAR mice include a gene regulato-
ry component. It is unlikely that all of the observed
gene regulatory effects occur directly via PPARα,
because the GLUT4 and PFK genes are not known
PPARα targets. However, expression of PDK4 has been
shown to be activated by PPARα ligands (40). It is like-
ly that GLUT4 and PFK gene expression is repressed via
PPARα-independent transcriptional regulatory path-
ways linked to alterations in cellular energy metabo-
lism induced by PPARα. The observation that glucose
uptake and utilization can be altered in heart second-
ary to PPARα-mediated increases in fatty acid utiliza-
tion suggests the intriguing possibility that some
forms of insulin resistance or type 2 diabetes could be
due to alterations in components of the PPARα regu-
latory complex or downstream genes involved in cellu-
lar fatty acid utilization.
Acknowledgments
Special thanks to Richard Boriak for technical assis-
tance with the CPT I assays, Terry Sharp for her assis-
tance with the microPET studies, and Mary Wingate
for help with manuscript preparation. We thank J.E.
Schaffer, R.V. Farese, M. Mueckler, R.A. Harris, E.G.
Kranias, and T. Hashimoto for cDNAs and antibodies.
The histologic studies were performed in the Digestive
Diseases Research Core Center at Washington Univer-
sity. B.N. Finck is supported by an individual National
Research Service Award (grant F32 HL67575) from the
National Heart, Lung, and Blood Institute (NIH). This
work was supported by NIH grants RO1 DK45416, P30
DK56341, P30 DK52574, PO1 HL5727805, PO1
HL13851, and JDFI 996003.
1. Kannel, W.B., Hjortland, M., and Castelli, W.P. 1974. Role of diabetes in
congestive heart failure: the Framingham study. Am. J. Cardiol. 34:29–34.
2. Rubler, S., et al. 1972. New type of cardiomyopathy associated with
glomerulosclerosis. Am. J. Cardiol. 30:595–602.
3. Stanley, W.C., Lopaschuk, G.D., and McCormack, J.G. 1997. Regulation
of energy substrate metabolism in the diabetic heart. Cardiovasc. Res.
34:25–33.
4. Rodrigues, B., Cam, M.C., and McNeill, J.H. 1995. Myocardial substrate
metabolism: implications for diabetic cardiomyopathy. J. Mol. Cell. Car-
diol. 27:169–179.
5. Neely, J.R., Rovetto, M.J., and Oram, J.F. 1972. Myocardial utilization of
carbohydrate and lipids. Prog. Cardiovasc. Dis. 15:289–329.
6. Lopaschuk, G.D., and Spafford, M. 1989. Response of isolated working
hearts to fatty acids and carnitine palmitoyltransferase 1 inhibition dur-
ing reduction of coronary flow in acutely and chronically diabetic rats.
Circ. Res. 65:378–387.
7. Murthy, V.K., and Shipp, J.C. 1977. Accumulation of myocardial triacyl-
glycerols in ketotic diabetes. Diabetes. 26:222–229.
8. Paulson, D.J., and Crass, M.F. 1982. Endogenous triacylglycerol metab-
olism in diabetic heart. Am. J. Physiol. 242:1084–1094.
9. Zhou, Y.T., et al. 2000. Lipotoxic heart disease in obese rats: implications
for human disease. Proc. Natl. Acad. Sci. USA. 97:1784–1789.
10. Chiu, H.-C., et al. 2001. A novel mouse model of lipotoxic cardiomyopa-
thy. J. Clin. Invest. 107:813–822.
11. Barger, P.M., and Kelly, D.P. 2000. PPAR signaling in the control of car-
diac energy metabolism. Trends Cardiovasc. Med. 10:238–245.
12. Lee, S.S.T., et al. 1995. Targeted disruption of the α isoform of the per-
oxisome proliferator-activated receptor gene in mice results in abolish-
ment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol.
15:3012–3022.
13. Djouadi, F., et al. 1998. A gender-related defect in lipid metabolism and
glucose homeostasis in peroxisome proliferator-activated receptor α-
deficient mice. J. Clin. Invest. 102:1083–1091.
14. Aoyama, T., et al. 1998. Altered constitutive expression of fatty acid-
metabolizing enzymes in mice lacking the peroxisome proliferator-acti-
vated receptor α (PPARα). J. Biol. Chem. 273:5678–5684.
15. Leone, T.C., Weinheimer, C.J., and Kelly, D.P. 1999. A critical role for the
peroxisome proliferator-activated receptor alpha (PPARα) in the cellu-
lar fasting response: the PPARα-null mouse as a model of fatty acid oxi-
dation disorders. Proc. Natl. Acad. Sci. USA. 96:7473–7478.
16. Kersten, S., et al. 1999. Peroxisome proliferator-activated receptor α
The Journal of Clinical Investigation | January 2002 | Volume 109 | Number 1 129
Downloaded on June  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/14080
mediates the adaptive response to fasting. J. Clin. Invest. 103:1489–1498.
17. Asayama, K., et al. 1999. Increased peroxisomal fatty acid β-oxidation
and enhanced expression of peroxisome proliferator-activator receptor-
α in diabetic rat liver. Mol. Cell. Biochem. 194:227–234.
18. Memon, R.A., et al. 2000. Up-regulation of peroxisome proliferator-acti-
vated receptors (PPAR-alpha) and PPAR-gamma mRNA expression in
the liver in murine obesity: troglitazone induces expression of PPAR-
gamma-responsive adipose tissue-specific genes in the liver of obese dia-
betic mice. Endocrinology. 141:4021–4031.
19. Kroetz, D.L., Yook, P., Costet, P., Bianchi, P., and Pineau, T. 1998. Perox-
isome proliferator-activated receptor α controls the hepatic CYP4A
induction adaptive response to starvation and diabetes. J. Biol. Chem.
273:31581–31589.
20. Belke, D.D., Larsen, T.S., Lopaschuk, G.D., and Severson, D.L. 1999. Glu-
cose and fatty acid metabolism in the isolated working mouse heart. Am.
J. Physiol. 277:R1210–R1217.
21. Cresci, S., Wright, L.D., Spratt, J.A., Briggs, F.N., and Kelly, D.P. 1996.
Activation of a novel metabolic gene regulatory pathway by chronic
stimulation of skeletal muscle. Am. J. Physiol. 270:C1413–C1420.
22. Esser, V., Brown, N.F., Cowan, A.T., Foster, D.W., and McGarry, J.D. 1996.
Expression of a cDNA isolated from rat brown adipose tissue and heart
identifies the product as the muscle isoform of carnitine palmitoyl-
transferase I (M-CPT I). J. Biol. Chem. 271:6972–6977.
23. Han, X., and Gross, R.W. 2001. Quantitative analysis and molecular
species finger printing of triglyceride molecular species directly from
lipid extracts of biological samples by electrospray ionization tandem
mass spectrometry. Anal. Biochem. 295:88–100.
24. Young, M.E., et al. 2001. Uncoupling protein 3 transcription is regulat-
ed by peroxisome proliferator-activated receptor α in the adult rodent
heart. FASEB J. 15:833–845.
25. Depre, C., et al. 2000. Streptozotocin-induced changes in cardiac gene
expression in the absence of severe contractile dysfunction. J. Mol. Cell.
Cardiol. 32:985–996.
26. Belke, D.D., Larsen, T.S., Gibbs, E.M., and Severson, D.L. 2000. Altered
metabolism causes cardiac dysfunction in perfused hearts from diabet-
ic (db/db) mice. Am. J. Physiol. 279:E1104–E1113.
27. Wu, P., et al. 1998. Starvation and diabetes increase the amount of pyru-
vate dehydrogenase kinase isoenzyme 4 in rat heart. Biochem. J.
329:197–201.
28. Ahmed, S.S., Jaferi, G.A., Narang, R.M., and Regan, T.J. 1975. Preclinical
abnormality of left ventricular function in diabetes mellitus. Am. Heart
J. 89:153–158.
29. Dillmann, W.H. 1988. Diabetes mellitus-induced changes in the con-
centration of specific mRNAs and proteins. Diabetes Metab. Rev.
4:789–797.
30. Taegtmeyer, H., Goodwin, G.W., Doenst, T., and Frazier, O.H. 1997. Sub-
strate metabolism as a determinant for postischemic functional recov-
ery of the heart. Am. J. Cardiol. 80:3A–10A.
31. Lewandowski, E.D., and White, L.T. 1995. Pyruvate dehydrogenase influ-
ences postischemic heart function. Circulation. 91:2071–2079.
32. McVeigh, J.J., and Lopaschuk, G.D. 1990. Dichloroacetate stimulation
of glucose oxidation improves recovery of ischemic rat hearts. Am. J. Phys-
iol. 259:H1079–H1085.
33. Tian, R., and Abel, E.D. 2001. Responses of GLUT4-deficient hearts to
ischemia underscore the importance of glycolysis. Circulation.
103:2961–2966.
34. Randle, P.J., Hales, C.N., and Garland, P.B. 1963. The glucose fatty-acid
cycle. Its role in insulin sensitivity and the metabolic disturbances of dia-
betic mellitus. Lancet. 1:785–789.
35. Frayne, K.N. 1993. Insulin resistance and lipid metabolism. Curr. Opin.
Lipidol. 4:197–204.
36. McGarry, J.D. 1992. What if Minkowski had been ageusic? An alterna-
tive angle on diabetes. Science. 258:766–770.
37. Dresner, A., et al. 1999. Effects of free fatty acids on glucose transport
and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest.
103:253–259.
38. Griffin, M.E., et al. 1999. Free fatty acid-induced insulin resistance is
associated with activity of protein kinase C theta and alterations in the
insulin signaling cascade. Diabetes. 48:1270–1274.
39. Kim, J.K., et al. 2001. Tissue-specific overexpression of lipoprotein lipase
causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. USA.
98:7522–7527.
40. Wu, P., Inskeep, K., Bowker-Kinley, M.M., Popov, K.M., and Harris, R.A.
1999. Mechanism responsible for inactivation of skeletal muscle pyru-
vate dehydrogenase complex in starvation and diabetes. Diabetes.
48:1593–1599.
130 The Journal of Clinical Investigation | January 2002 | Volume 109 | Number 1
Downloaded on June  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/14080
